WCC 2006: Final heart failure trial heralds upturn in fortunes for Vasogen
This article was originally published in Clinica
Executive Summary
Vasogen's novel heart failure immunotherapy device, which failed to meet a key trial endpoint earlier this year, is actually effective in as many as 70% of the study patients assessed, a final analysis of the trial has revealed.